Find out a little about Hailey Gilmore in her interesting mini-bio, the latest in IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Hailey is one of five new bios we are featuring.  Hailey GilmoreSan Francisco, California, USA Hailey Gilmore studied international development in college and was always interested in sexual health promotion Read More >>

Check out this interesting mini-bio of  Coco Alinsug, the latest in IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Coco is one of five new bios posted this week.   Coco AlinsungBoston, Massachusettes, USA A native of the Philippines and a resident of Lynn, Massachusetts with his partner, Coco Alinsug has made a Read More >>

This post by IRMA’s Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance. The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out Read More >>

[Click here for the VOICE press release – “Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study” – from the Microbcide Trials Network] IRMA, like the rest of new prevention technology researchers and advocates, is disappointed to learn that daily oral Truvada was not found to be an effective HIV intervention among the African women at Read More >>

via PLoS Medicine, by Gordon Mansergh, Beryl A. Koblin, Patrick S. Sullivan Summary Points: Pre-exposure prophylaxis (PrEP) with anti-retroviral (ARV) medications is partially efficacious for preventing HIV infection among men who have sex with men (MSM) and heterosexuals. As PrEP becomes available and prescribed for use among MSM a better understanding of willingness to use PrEP and Read More >>

via IRMA/AVAC, presented by Jim A. Turpin Please register for this teleconference.  Meeting Description: In the last two years there has been great progress in ARV-based prevention strategies – both in terms of PrEP and microbicides. Specifically, there has been enormous excitement and promise around two drugs – tenofovir and Truvada. And more recently, studies testing Dapivirine Read More >>

via Citizen News Service, by Bobby Ramakant At the recently concluded XIX International AIDS Conference (AIDS 2012), not only the decibels went up on ending AIDS but also sane voices were heard demanding a well-costed and thought-through strategy on how to end AIDS. One of the strategies that will complement a comprehensive HIV prevention, treatment, care and Read More >>

 via aidsmap, by Gus Cairns How do we stop the hyperepidemic in gay men? A number of presentations at the 19th International AIDS Conference explored the ‘hyperepidemic’ of HIV amongst men who have sex with men, and especially black MSM. A paper presented by Gregorio Millet (pictured above at a White House reception honoring people working in AIDS) showed that, at Read More >>

via Morbidity and Mortality Weekly Report In the United States, an estimated 48,100 new human immunodeficiency virus (HIV) infections occurred in 2009 (1). Of these, 27% were in heterosexual men and women who did not inject drugs, and 64% were in men who have sex with men (MSM), including 3% in MSM who inject drugs. In January Read More >>

[Press release from AIDS Foundation of Chicago – home to IRMA] Historic decision makes Truvada the first drug approved to reduce the risk of HIV infection from sexual contact among HIV-negative individuals at elevated risk of infection Today, the U.S. Food and Drug Administration approved the use of Gilead’s  antiretroviral drug Truvada for HIV prevention — known Read More >>